Template:ID-Fungal meningitis: Difference between revisions
Gerald Chi- (talk | contribs) mNo edit summary |
Gerald Chi- (talk | contribs) mNo edit summary |
||
| Line 1: | Line 1: | ||
* Fungal meningitis | * Fungal meningitis | ||
:* '''Blastomyces dermatitidis''' | :* '''Blastomyces dermatitidis'''<ref>{{Cite journal| doi = 10.1086/588300| issn = 1537-6591| volume = 46| issue = 12| pages = 1801–1812| last1 = Chapman| first1 = Stanley W.| last2 = Dismukes| first2 = William E.| last3 = Proia| first3 = Laurie A.| last4 = Bradsher| first4 = Robert W.| last5 = Pappas| first5 = Peter G.| last6 = Threlkeld| first6 = Michael G.| last7 = Kauffman| first7 = Carol A.| last8 = Infectious Diseases Society of America| title = Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America| journal = Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America| date = 2008-06-15| pmid = 18462107}}</ref> | ||
::* Preferred regimen: [[Liposomal Amphotericin B]] 5 mg/kg/day IV for 4—6 weeks, followed by [[Fluconazole]] 800 mg PO qd {{or}} [[Itraconazole]] 200 mg PO bid—tid {{or}} [[Voriconazole]] 200—400 mg PO bid for ≥12 months until CSF abnl resolves | ::* Preferred regimen: [[Liposomal Amphotericin B]] 5 mg/kg/day IV for 4—6 weeks, followed by [[Fluconazole]] 800 mg PO qd {{or}} [[Itraconazole]] 200 mg PO bid—tid {{or}} [[Voriconazole]] 200—400 mg PO bid for ≥12 months until CSF abnl resolves | ||
Revision as of 00:20, 20 June 2015
- Fungal meningitis
- Blastomyces dermatitidis[1]
- Preferred regimen: Liposomal Amphotericin B 5 mg/kg/day IV for 4—6 weeks, followed by Fluconazole 800 mg PO qd OR Itraconazole 200 mg PO bid—tid OR Voriconazole 200—400 mg PO bid for ≥12 months until CSF abnl resolves
- Candida spp.
Preferred Regimen ▸ Liposomal Amphotericin B 3—5 mg/kg/day IV WITH OR WITHOUT ▸ Flucytosine 25 mg/kg PO qid Alternative Regimen ▸ Fluconazole 400—800 mg PO qd (6—12 mg/kg IV q24h) OR ▸ Voriconazole 400 mg PO bid × 2 doses FOLLOWED BY 200 mg PO bid OR ▸ Voriconazole 6 mg/kg IV q12h × 2 doses FOLLOWED BY 3 mg/kg IV q12h Adapted from Clin Infect Dis. 2009;48(5):503-35.[8]
- Coccidioides immitis
Preferred Regimen ▸ Fluconazole 400 mg PO qd Alternative Regimen ▸ Itraconazole 200 mg PO bid—tid Adapted from Clin Infect Dis. 2005;41(9):1217-23.[9]
- C. neoformans, HIV–infected
Induction Therapy: Preferred Regimen 1 ▸ Amphotericin B 0.7—1.0 mg/kg IV q24h for ≥2 weeks OR ▸ Liposomal Amphotericin B 3—4 mg/kg IV q24h for ≥2 weeks OR ▸ Amphotericin B lipid complex 5 mg/kg IV q24h for ≥2 weeks PLUS ▸ Flucytosine 25 mg/kg PO q6h for ≥2 weeks Induction Therapy: Preferred Regimen 2 ▸ Amphotericin B 0.7—1.0 mg/kg IV q24h for 4—6 weeks OR ▸ Liposomal Amphotericin B 3—4 mg/kg IV q24h for 4—6 weeks OR ▸ Amphotericin B lipid complex 5 mg/kg IV q24h for 4—6 weeks Induction Therapy: Alternative Regimen 1 ▸ Amphotericin B 0.7 mg/kg IV q24h for 2 weeks PLUS ▸ Fluconazole 800 mg PO q24h for 2 weeks Induction Therapy: Alternative Regimen 2 ▸ Fluconazole 1200 mg PO q24h for 6 weeks PLUS ▸ Flucytosine 100 mg/kg PO q24h for 6 weeks Induction Therapy: Alternative Regimen 3 ▸ Fluconazole 800—2000 mg PO q24h for 10—12 weeks Induction Therapy: Alternative Regimen 4 ▸ Itraconazole 200 mg PO q12h for 10—12 weeks Consolidation Therapy ▸ Fluconazole 400 mg PO q24h for 8 weeks Maintenance Therapy ▸ Fluconazole 200 mg PO q24h for ≥1 year OR ▸ Itraconazole 400 mg PO q24h for ≥1 year OR ▸ Amphotericin B 1.0 mg/kg/week IV for ≥1 year
- C. neoformans, Organ Transplant Recipients
Induction Therapy: Preferred Regimen ▸ Liposomal Amphotericin B 3—4 mg/kg IV q24h for ≥2 weeks OR ▸ Amphotericin B lipid complex 5 mg/kg IV q24h for ≥2 weeks PLUS ▸ Flucytosine 25 mg/kg PO q6h for ≥2 weeks Induction Therapy: Alternative Regimen ▸ Liposomal Amphotericin B 3—4 mg/kg IV q24h for 4—6 weeks OR ▸ Amphotericin B lipid complex 5 mg/kg IV q24h for 4—6 weeks Consolidation Therapy ▸ Fluconazole 400—800 mg PO q24h for 8 weeks Maintenance Therapy ▸ Fluconazole 200—400 mg PO q24h for 6—12 months
- C. neoformans, Non–HIV-Infected and Nontransplant Hosts
Induction Therapy: Preferred Regimen ▸ Amphotericin B 0.7—1.0 mg/kg IV q24h for 4—6 weeks OR ▸ Liposomal Amphotericin B 3—4 mg/kg IV q24h for 4—6 weeks OR ▸ Amphotericin B lipid complex 5 mg/kg IV q24h for 4—6 weeks PLUS ▸ Flucytosine 25 mg/kg PO q6h for 4—6 weeks Consolidation Therapy ▸ Fluconazole 400—800 mg PO q24h for 8 weeks Maintenance Therapy ▸ Fluconazole 200 mg PO q24h for 6—12 months Adapted from Clin Infect Dis. 2010;50(3):291-322.[10]
- Histoplasma capsulatum
Preferred Regimen ▸ Liposomal Amphotericin B 5 mg/kg IV q24h for 4—6 weeks FOLLOWED BY ▸ Itraconazole 200 mg PO bid—tid for ≥12 months Adapted from Clin Infect Dis. 2007;45(7):807-25.[11]
- ↑ Chapman, Stanley W.; Dismukes, William E.; Proia, Laurie A.; Bradsher, Robert W.; Pappas, Peter G.; Threlkeld, Michael G.; Kauffman, Carol A.; Infectious Diseases Society of America (2008-06-15). "Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America". Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 46 (12): 1801–1812. doi:10.1086/588300. ISSN 1537-6591. PMID 18462107.